CDK15/CCNA2(CDK15/cyclin A2)
Sign in to save this workspaceUniProt CDK15: Q96Q40; cyclin A2: P20248 · PDB · AlphaFold (Q96Q40), AlphaFold (P20248) · Substrate: RB Protein · Clone: (aa103-387)/full length
Top inhibitors
| # | Drug | Inhibition | Residual | KISS | Gini |
|---|---|---|---|---|---|
| 1 | Defactinib | 70.5% | 29.5% | 92.68 | 0.450 |
| 2 | Pralsetinib | 41.8% | 58.2% | 93.43 | 0.643 |
| 3 | Crizotinib | 27.0% | 73.0% | 91.39 | 0.581 |
| 4 | Ponatinib | 22.6% | 77.4% | 78.23 | 0.534 |
| 5 | Ceritinib | 13.8% | 86.3% | 95.44 | 0.618 |
| 6 | Pexidartinib | 11.8% | 88.2% | 99.49 | 0.631 |
| 7 | Fedratinib | 7.8% | 92.2% | 96.21 | 0.576 |
| 8 | Alpelisib | 7.5% | 92.5% | 97.22 | 0.720 |
| 9 | Pacritinib | 6.3% | 93.7% | 88.64 | 0.452 |
| 10 | Repotrectinib | 6.2% | 93.8% | 84.21 | 0.608 |
| 11 | Upadacitinib | 6.1% | 93.9% | 97.98 | 0.663 |
| 12 | Entrectinib | 6.1% | 93.9% | 93.69 | 0.671 |
| 13 | Tucatinib | 5.6% | 94.4% | 99.75 | 0.652 |
| 14 | Quizartinib | 5.4% | 94.6% | 99.50 | 0.737 |
| 15 | Tepotinib | 5.2% | 94.8% | 99.75 | 0.727 |
| 16 | Capivasertib | 5.0% | 95.0% | 96.48 | 0.644 |
| 17 | Futibatinib | 5.0% | 95.0% | 98.48 | 0.718 |
| 18 | Avapritinib | 4.9% | 95.1% | 97.73 | 0.644 |
| 19 | Rabusertib | 4.6% | 95.4% | 98.74 | 0.687 |
| 20 | Canertinib | 2.9% | 97.1% | 96.49 | 0.671 |
Paralog block
No paralog group registered for this kinase.
EMT expression
Not in the EMT expression panel.
Selectivity landscape vs inhibition on CDK15/CCNA2
Each point is one of the 92 approved drugs; color = inhibition % on CDK15/CCNA2.
3D structure
Embedded NGL viewer pulls a representative PDB entry (or AlphaFold model if no experimental structure is registered). Heavy bundle — loaded only on demand.
Annotations
Sign in to read and post annotations.
Loading…